Last updated: August 24, 2026
PANRETIN, the 0.1% alitretinoin topical gel, is a small, specialized oncology product approved for localized cutaneous lesions associated with AIDS-related Kaposi's sarcoma. Its commercial value is constrained by the declining incidence of AIDS-related Kaposi's sarcoma, limited treatment duration, narrow clinical use, and the absence of publicly reported product-level revenue. The product has no meaningful biologic or biosimilar exposure, while generic and alternative-treatment risk remains the main long-term commercial issue.
What is PANRETIN and what is it approved to treat?
PANRETIN contains alitretinoin, a retinoid related to vitamin A. FDA approved the product in 1999 for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma when the lesions are not suitable for systemic therapy or other local treatment [1].
The product is supplied as a 0.1% gel for external use. It is applied directly to lesions, generally beginning with twice-daily administration and increasing frequency as tolerated. Treatment is local and does not treat visceral or pulmonary Kaposi's sarcoma [1].
PANRETIN product profile
| Attribute |
Detail |
| Brand |
PANRETIN |
| Active ingredient |
Alitretinoin |
| Dosage form |
Topical gel |
| Strength |
0.1% |
| FDA application |
NDA 020443 |
| Initial FDA approval |
1999 |
| Primary indication |
Cutaneous lesions associated with AIDS-related Kaposi's sarcoma |
| Regulatory pathway |
New drug application |
| Product type |
Small-molecule topical oncology drug |
| Biosimilar exposure |
None |
| Main competitors |
Local radiation, cryotherapy, intralesional therapy, systemic chemotherapy, antiretroviral therapy, and off-label topical treatments |
PANRETIN was developed for a narrow population. Its clinical use depends on lesion location, symptom burden, prior treatment, immune status, and the availability of local treatment.
What is the FDA regulatory status of PANRETIN?
PANRETIN received FDA approval based on clinical data showing activity against cutaneous Kaposi's sarcoma lesions. The product remains a prescription drug regulated under an approved NDA, subject to labeling, manufacturing, pharmacovigilance, and distribution requirements.
The FDA label identifies Eisai Inc. as the manufacturer or marketing company in U.S. product materials [1]. Public FDA records have not established a new indication, supplemental approval, or major label expansion that materially changes PANRETIN's market opportunity.
What was PANRETIN's orphan-drug exclusivity period?
PANRETIN qualified for orphan-drug treatment because AIDS-related Kaposi's sarcoma affects a small patient population. The seven-year orphan-drug exclusivity period associated with the 1999 approval would have expired in 2006, assuming the standard statutory period ran from approval.
Orphan exclusivity prevented FDA approval of the same drug for the same indication during the exclusivity term, subject to statutory exceptions. It did not create a perpetual barrier against later generic development, alternative formulations, or competing therapies.
PANRETIN's principal regulatory protections are therefore historical rather than current. The commercial product does not depend on an active orphan-exclusivity period.
What patents protect PANRETIN?
PANRETIN's original patent protection is not expected to provide a material current barrier to generic entry. The historic patent estate covered topical retinoid compositions and related formulations rather than a broad, perpetual monopoly over alitretinoin therapy.
A historically relevant U.S. patent associated with topical retinoid formulations is U.S. Patent No. 5,618,839. Its term would have ended no later than the statutory 20-year period measured from the applicable nonprovisional filing date, subject to any patent-term adjustment or extension. It does not create a current long-term exclusivity position for PANRETIN.
Patent and exclusivity assessment
| Protection category |
PANRETIN position |
Commercial effect |
| Orphan-drug exclusivity |
Expired after the statutory seven-year period |
No current orphan barrier |
| Original formulation patents |
Historic patents have reached or approached expiry |
Limited current protection |
| Orange Book patents |
No publicly evident unexpired patent position that creates a durable barrier |
Paragraph IV risk depends on current listings and FDA records |
| Pediatric exclusivity |
No material public evidence of a six-month pediatric extension |
No known current impact |
| New chemical entity exclusivity |
Expired |
No current NCE protection |
| Trade secrets |
Manufacturing and formulation know-how may remain protected |
Potential technical barrier, not regulatory exclusivity |
| Trademarks |
PANRETIN brand rights may remain relevant |
Brand differentiation only |
An exact current Orange Book patent position must be determined from the live FDA listing and the applicable reference-date edition. The public commercial logic remains clear: PANRETIN's principal patents and regulatory exclusivities are mature, while its remaining protection is based more on brand, supply continuity, physician familiarity, and the small size of the market.
What is the Orange Book status of PANRETIN?
PANRETIN is associated with FDA NDA 020443 and is treated as a small-molecule prescription product rather than a biologic. Any ANDA applicant would generally need to address the reference listed drug's active ingredient, dosage form, strength, route, labeling, and applicable patent certifications.
The practical Orange Book risk has three components:
- A generic applicant could seek approval for alitretinoin gel 0.1%.
- The applicant could submit a Paragraph IV certification against any listed patent that remains unexpired.
- If no enforceable listed patent remains, the applicant could proceed through an ordinary abbreviated pathway subject to FDA approval and commercial economics.
How relevant are Paragraph IV challenges?
No widely reported, commercially significant Paragraph IV litigation campaign against PANRETIN has established a current market event comparable with major blockbuster products. That absence is consistent with the product's small addressable population and uncertain generic economics.
A Paragraph IV filing would still be possible if a manufacturer identified a viable formulation, manufacturing process, or market opportunity. The risk is more likely to arise from a low-cost topical manufacturer or specialty-generic company than from a large generic company seeking a high-volume product.
When does PANRETIN lose exclusivity?
PANRETIN lost its principal regulatory exclusivity years ago. The orphan-drug period would have ended around 2006, and historical patent protection would have expired on the ordinary patent timetable. The product therefore has no obvious remaining exclusivity cliff comparable with a major branded drug approaching loss of market protection.
The commercial question is not when PANRETIN loses exclusivity. It is whether a generic entrant can earn an adequate return after development, FDA review, manufacturing validation, distribution costs, and the low volume of eligible patients.
How large is the PANRETIN market?
PANRETIN addresses a shrinking and geographically concentrated market. The number of patients with AIDS-related Kaposi's sarcoma has declined in countries with broad access to combination antiretroviral therapy. Antiretroviral treatment can improve immune function and reduce the incidence or severity of Kaposi's sarcoma, although lesions can persist and still require local therapy [2].
The market is also limited by the product's positioning. PANRETIN is not a first-line systemic treatment for advanced disease. It is most relevant to patients with accessible cutaneous lesions who need local treatment and are not appropriate candidates for radiation, surgery, cryotherapy, or systemic therapy.
Market drivers
| Driver |
Direction |
Effect on PANRETIN |
| Wider antiretroviral access |
Negative for disease incidence |
Shrinks the untreated and newly diagnosed population |
| Persistent lesions in treated patients |
Positive |
Preserves a niche maintenance and local-treatment market |
| Need to avoid systemic toxicity |
Positive |
Supports topical treatment in selected patients |
| Alternative local therapies |
Negative |
Limits pricing power and prescribing volume |
| Generic development |
Negative |
Could reduce price and branded share |
| Specialty-pharmacy distribution |
Mixed |
Supports controlled access but adds friction |
| Rare-disease treatment economics |
Positive for price, negative for volume |
Can sustain revenue per patient without creating scale |
What is PANRETIN's financial trajectory?
Eisai has not publicly disclosed a separate PANRETIN revenue line in its major financial reporting. The product is not reported as a standalone material contributor to consolidated revenue, and public filings do not provide a reliable annual sales series for the brand.
PANRETIN's financial trajectory is therefore best characterized as mature, niche, and commercially stable only to the extent that the product retains a small base of patients and avoids a direct generic substitute.
Revenue trajectory by phase
| Period |
Commercial phase |
Financial implication |
| 1999-2006 |
Launch and orphan exclusivity |
Premium pricing supported by regulatory protection and limited competition |
| 2007-2015 |
Post-exclusivity branded period |
Revenue depended on physician familiarity, supply, and limited alternatives |
| 2016-present |
Mature specialty product |
Volume pressure from disease decline; price and distribution determine gross revenue |
| Future |
Generic or supply disruption scenario |
Potential price compression and loss of branded share |
A rough revenue model would be:
Revenue = treated patients x tubes per patient x net price per tube.
Each variable is difficult to estimate from public information. Treatment can extend for weeks or months, but dose frequency varies with tolerance and response. Net pricing also varies by payer, specialty pharmacy, patient assistance, and contractual discounts. Without company-disclosed units and net price, an exact revenue estimate would not be reliable.
What is the revenue exposure to PANRETIN?
PANRETIN is unlikely to represent a material share of Eisai's consolidated revenue. Eisai's financial profile is driven by larger specialty and oncology products, including products with substantially broader patient populations and higher reported sales. PANRETIN's contribution is more relevant as a niche-product cash-flow asset than as a strategic growth engine [3].
Its economic value can include:
- recurring demand from a specialized patient group;
- low promotional requirements;
- brand recognition among HIV and oncology specialists;
- potential pricing resilience because of the limited number of approved topical options;
- strategic value as part of a specialty pharmaceutical portfolio.
Its weaknesses include:
- declining disease incidence;
- low volume;
- limited ability to expand the indication;
- potential substitution by compounded or off-label topical products;
- exposure to manufacturing interruptions;
- lack of patent-based pricing protection.
Which companies are challenging PANRETIN?
No major publicly visible challenger has established a sustained, high-profile branded competition program against PANRETIN. The relevant competitive threat is fragmented.
Generic and alternative competitors
Potential competitors include:
- generic alitretinoin gel, if an ANDA is approved;
- compounded alitretinoin or related retinoid preparations;
- topical tretinoin used off label;
- cryotherapy;
- local radiation;
- intralesional vinblastine;
- liposomal doxorubicin for more extensive disease;
- antiretroviral therapy as disease-directed management.
These products do not have identical regulatory status or clinical positioning. A generic alitretinoin gel would pose the most direct substitution risk because it could be therapeutically and pharmaceutically equivalent to PANRETIN.
What formulation patents protect PANRETIN?
The commercial formulation is a topical gel containing 0.1% alitretinoin. Historic formulation patents may have covered retinoid solubilization, gel vehicles, stabilizers, penetration, and topical delivery. Those patents are materially less important today because the core patent terms have expired or are near the end of their enforceable lives.
Manufacturing know-how can still create a practical barrier. Alitretinoin is sensitive to light and oxidation, and retinoid formulations require controlled handling, packaging, stability testing, and quality assurance. These issues can slow generic development but do not substitute for an unexpired patent.
What manufacturing and intellectual-property barriers affect PANRETIN?
The primary technical barriers are formulation stability, reproducible active-ingredient dispersion, packaging that protects the product from light and degradation, and validated shelf life. These barriers affect development cost and supply reliability.
They are not equivalent to exclusivity. A capable generic manufacturer could overcome them through formulation development, comparative testing, process validation, and FDA review.
The product's small market may be the stronger barrier. A company may face insufficient volume to justify development, especially if PANRETIN's net price falls after generic entry.
What patent litigation affects PANRETIN?
No major current patent litigation involving PANRETIN has produced a well-known settlement, launch restriction, or damages exposure comparable with litigation involving large oncology or immunology brands.
The absence of major litigation reflects the product's size and mature patent position. If a future generic filing occurs, the likely dispute would center on any surviving Orange Book-listed patent, formulation differences, labeling, or manufacturing claims. A settlement could delay launch, but there is no established public settlement framework currently shaping the product's market.
Does PANRETIN face biosimilar risk?
No. PANRETIN is a chemically synthesized small-molecule topical drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply.
The relevant pathway is generic-drug competition under an ANDA, not a 351(k) biosimilar application. This distinction matters because a generic applicant can pursue therapeutic equivalence without repeating the full clinical development program required for an original new drug.
How does PANRETIN compare with competing treatments?
| Treatment |
Main role |
Advantage versus PANRETIN |
Limitation versus PANRETIN |
| PANRETIN gel |
Local cutaneous lesions |
Noninvasive and locally delivered |
Slow response, irritation, narrow indication |
| Cryotherapy |
Small superficial lesions |
Rapid local treatment |
Pain, pigment change, limited suitability |
| Radiation |
Local or symptomatic lesions |
Strong local control |
Facility-based treatment and cumulative toxicity |
| Intralesional therapy |
Selected lesions |
Direct lesion treatment |
Injection burden and variable availability |
| Liposomal doxorubicin |
Extensive or systemic disease |
Treats broader disease burden |
Systemic toxicity and infusion requirements |
| Antiretroviral therapy |
HIV and disease control |
Addresses underlying immune suppression |
May not remove established lesions quickly |
| Topical tretinoin |
Off-label local use |
Potentially accessible and inexpensive |
No PANRETIN-equivalent FDA indication |
PANRETIN's strongest commercial position is in patients who need local treatment but want to avoid invasive procedures, radiation, or systemic chemotherapy.
What generic launch scenarios exist for PANRETIN?
Scenario 1: No generic entry
PANRETIN remains a small branded specialty product. Revenue declines gradually as the underlying patient population contracts, while pricing remains relatively resilient.
Scenario 2: Single generic entrant
A first approved generic could produce a meaningful price reduction and capture payer-preferred volume. PANRETIN could retain patients who prefer the branded product or experience coverage barriers with the generic.
Scenario 3: Multiple generic entrants
Price competition would intensify. The product could move toward a low-margin commodity market, although limited demand may discourage numerous entrants.
Scenario 4: Supply disruption without generic entry
A manufacturing or distribution interruption could create temporary shortages and shift physicians toward compounded preparations or alternative local therapies. For a small product, supply continuity is a material competitive asset.
What is the geographic coverage of PANRETIN?
PANRETIN's commercial opportunity is concentrated in the United States and selected markets with:
- substantial HIV treatment access;
- reimbursement for specialty dermatology or oncology products;
- established specialty-pharmacy channels;
- regulatory recognition of topical alitretinoin for AIDS-related Kaposi's sarcoma.
Geographic expansion is constrained by the narrow indication and declining disease burden in high-income countries. Lower-income markets may have greater untreated HIV burden but weaker reimbursement and lower ability to support branded specialty pricing.
Key Takeaways
- PANRETIN is a mature topical alitretinoin product for cutaneous AIDS-related Kaposi's sarcoma.
- FDA approval dates to 1999, and its seven-year orphan exclusivity period has expired.
- Historical formulation and topical-retinoid patents do not appear to provide a durable present-day exclusivity position.
- No biosimilar risk exists because PANRETIN is a small-molecule drug.
- Generic alitretinoin gel is the principal direct substitution risk, although market size may limit developer interest.
- AIDS-related Kaposi's sarcoma incidence has declined with antiretroviral treatment, reducing long-term volume potential.
- Eisai does not publicly report PANRETIN as a standalone revenue product, so exact sales and margin trends cannot be established from company filings.
- PANRETIN's value is that of a niche specialty cash-flow product, not a growth asset.
- Manufacturing quality, stability, supply continuity, and physician familiarity may matter more than patent protection.
- The most likely financial trajectory is gradual erosion from disease contraction, with a sharper decline if an equivalent generic reaches the market.
FAQs
Is PANRETIN still FDA approved?
Yes. PANRETIN is associated with FDA NDA 020443 and is approved for topical treatment of cutaneous lesions associated with AIDS-related Kaposi's sarcoma.
Is alitretinoin the same as isotretinoin?
No. Alitretinoin and isotretinoin are different retinoids. PANRETIN contains alitretinoin, while isotretinoin is used primarily for severe acne and other indications.
Can PANRETIN treat internal Kaposi's sarcoma?
No. PANRETIN is a topical product for cutaneous lesions and does not treat visceral or pulmonary Kaposi's sarcoma.
Is PANRETIN available as an oral drug?
Oral alitretinoin products have been developed and marketed in some jurisdictions for other indications, including severe chronic hand eczema. Oral alitretinoin is not interchangeable with PANRETIN gel for the FDA-approved Kaposi's sarcoma indication.
Could a compounded alitretinoin gel replace PANRETIN?
A compounded product may be considered in some circumstances, but it is not automatically therapeutically equivalent to the FDA-approved product. Differences in formulation, stability, concentration, quality controls, labeling, and reimbursement affect substitution decisions.
References
-
U.S. Food and Drug Administration. (1999). PANRETIN (alitretinoin) gel, 0.1% prescribing information. FDA/DailyMed.
-
National Cancer Institute. (2024). Kaposi sarcoma treatment. https://www.cancer.gov/types/soft-tissue-sarcoma/patient/kaposi-sarcoma-treatment-pdq
-
Eisai Co., Ltd. (2024). Annual report and financial results materials. https://www.eisai.com/ir/library/annual.html
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,618,839. https://patents.google.com/patent/US5618839
